Kevin Cureton - 27 Dec 2023 Form 4 Insider Report for NANOPHASE TECHNOLOGIES Corp (SLSN)

Role
Chief Operating Officer
Signature
/s/ Jess Jankowski under UPA for Kevin Cureton
Issuer symbol
SLSN
Transactions as of
27 Dec 2023
Net transactions value
+$7,686
Form type
4
Filing time
29 Dec 2023, 16:00:17 UTC
Previous filing
05 Jun 2023
Next filing
24 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NANX Common Stock 100,821 27 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NANX Common Stock (right to purchase) Award $7,686 +12,600 $0.6100 12,600 27 Dec 2023 Common Stock 12,600 $0.6100 Direct F1
holding NANX Common Stock (right to purchase) 25,000 27 Dec 2023 Common Stock 25,000 $0.5200 Direct F1, F2
holding NANX Common Stock (right to purchase) 50,000 27 Dec 2023 Common Stock 50,000 $0.4400 Direct F1
holding NANX Common Stock (right to purchase) 43,500 27 Dec 2023 Common Stock 43,500 $0.4200 Direct F1
holding NANX Common Stock (right to purchase) 50,000 27 Dec 2023 Common Stock 50,000 $0.6800 Direct F1
holding NANX Common Stock (right to purchase) 80,000 27 Dec 2023 Common Stock 80,000 $0.8200 Direct F1
holding NANX Common Stock (right to purchase) 16,500 27 Dec 2023 Common Stock 16,500 $0.5100 Direct F1
holding NANX Common Stock (right to purchase) 90,000 27 Dec 2023 Common Stock 90,000 $0.4500 Direct F1
holding NANX Common Stock (right to purchase) 90,000 27 Dec 2023 Common Stock 90,000 $4.17 Direct F1
holding NANX Common Stock (right to purchase) 72,000 27 Dec 2023 Common Stock 72,000 $1.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
F2 Following the recently reported exercise of 12,393 shares (11/24/21), and the 2nd exercise of 12,607 shares (11/26/21, reported above) this line item represents the 3rd exercise, of 25,000 shares of the total initial grant of 75,000 shares, leaving a balance of 25,000 shares remaining relating to this grant.